EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects

Fan Yang, Pan-Pan Ye, Wen-Shuo Lv, Li-Ze Li, Bao-Zhong Zhao, John van denAnker, Xin-Mei Yang, Lin-Lin Song, Xiao-Ran Yang, Yi Zheng, Bo-Wen Ke, Wei Zhao iD

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70071 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Fan Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory …. Hauptthemen laut MEDLINE: Anesthetics, Intravenous, Etomidate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Taishan Scholar Project of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methoxyethyl etomidate hydrochloride (ET‐26) is a novel intravenous general anesthetic designed to address the clinical limitations of etomidate. This Phase I clinical trial assessed the pharmacokinetics, pharmacodynamics, drug–drug interaction (DDI) potential, and safety of ET‐26 in 68 healthy subjects across three sequences, evaluating interactions with rifampin (CYP2C19/3A4 inducer), fluconazole (CYP2C19/3A4 inhibitor), and omeprazole/midazolam. ET‐26 pharmacokinetic analyses showed that compared with administration of ET‐26 alone, co‐administration of rifampin resulted in a 10% decrease in the geometric mean ratio (GMR) of the AUC 0‐∞ for ET‐26 (GMR 90.0%, 90% CI 85.4%‐94.8%), while co‐administration fluconazole increased the AUC 0‐∞ by 18.5% (GMR 118.5%, 90% CI 111.4%‐126.2%). ET‐26 slightly increased the AUC 0‐∞ by 18.5% for omeprazole (GMR 118.5%, 90% CI 111.4%‐126.1%) and 11.1% for midazolam (GMR 111.1%, 90% CI 104.9%‐117.8%). The 90% CI for key parameters largely fell within no‐effect boundaries, indicating no clinically significant DDIs. Pharmacodynamic assessments showed consistent sedation profiles across sequences, with mild additive effects with midazolam. Safety evaluations identified treatment‐emergent adverse events such as injection site pain and myoclonus, more frequent with fluconazole. No serious adverse events were observed. These findings suggest ET‐26 exhibits a favorable safety and pharmacokinetic profile with no significant DDIs observed in clinical, supporting its potential as a safer alternative to etomidate for general anesthesia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anesthetics, IntravenousEtomidateAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveCross-Over StudiesCytochrome P-450 CYP2C19Drug InteractionsFluconazoleHealthy VolunteersMidazolamOmeprazoleRifampinAdolescent

Stichwörter der Autor:innen

Phase 1 clinical trialdrug–drug interactionetomidate analogsintravenous anestheticpharmacokinetics

Substanzen

Anesthetics, IntravenousCYP2C19 protein, humanCytochrome P-450 CYP2C19EtomidateFluconazoleMidazolamOmeprazoleRifampin

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pha…
  • Avanc Pharmaceutical Co., Ltd., Jinzhou, Liaoning, China.
  • Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
  • Departments of Pediatrics, Pharmacology & Physiology, Genomics and Precision Medicine, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
  • Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Devel…
  • Department of Anesthesiology, Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, C…

ORCID-Profile: Wei Zhao

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Taishan Scholar Project of Shandong Province
  • National Key Research and Development Program of China

Zitieren

APA

Yang, F., Ye, P. P., Lv, W. S., Li, L. Z., Zhao, B. Z., van denAnker, J., Yang, X. M., Song, L. L., Yang, X. R., Zheng, Y., Ke, B. W., & Zhao, W. (2025). Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70071

Vancouver

Yang F, Ye PP, Lv WS, Li LZ, Zhao BZ, van denAnker J, et al. Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70071

BibTeX
@article{Yang2025,
  author = {Yang, Fan and Ye, Pan-Pan and Lv, Wen-Shuo and Li, Li-Ze and Zhao, Bao-Zhong and van denAnker, John and Yang, Xin-Mei and Song, Lin-Lin and Yang, Xiao-Ran and Zheng, Yi and Ke, Bo-Wen and Zhao, Wei},
  title = {Methoxyethyl Etomidate Hydrochloride (ET‐26): A Phase I Clinical Trial Assessing Drug–Drug Interactions in Healthy Subjects},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70071}
}
Kostenlos starten →